These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15912115)

  • 1. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years.
    Singh N; Wannstedt C; Keyes L; Wagener MM; Gayowski T; Cacciarelli TV
    Transplantation; 2005 May; 79(10):1428-34. PubMed ID: 15912115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
    JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
    Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
    Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
    Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV
    Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
    Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
    Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
    Razonable RR
    World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
    Badley AD; Seaberg EC; Porayko MK; Wiesner RH; Keating MR; Wilhelm MP; Walker RC; Patel R; Marshall WF; DeBernardi M; Zetterman R; Steers JL; Paya CV
    Transplantation; 1997 Jul; 64(1):66-73. PubMed ID: 9233703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.
    Turgeon N; Fishman JA; Doran M; Basgoz N; Tolkoff-Rubin NE; Cosimi AB; Rubin RH
    Transpl Infect Dis; 2000 Mar; 2(1):2-10. PubMed ID: 11429003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
    McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST
    Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients.
    Onor IO; Todd SB; Meredith E; Perez SD; Mehta AK; Marshall Lyon G; Knechtle SJ; Hanish SI
    Transpl Int; 2013 Jun; 26(6):592-600. PubMed ID: 23590709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two strategies for prevention of cytomegalovirus infections after liver transplantation.
    Simon P; Sasse M; Laudi S; Petroff D; Bartels M; Kaisers UX; Bercker S
    World J Gastroenterol; 2016 Mar; 22(12):3412-7. PubMed ID: 27022223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy preemptive therapy with ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients].
    López-Medrano F; Lumbreras C; Otero JR; González-Alegre MT; San Juan R; Folgueira D; Lizasoaín M; Loinaz C; Moreno E; Aguado JM
    Med Clin (Barc); 2004 Jan; 122(2):41-5. PubMed ID: 14733853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients.
    Sun HY; Cacciarelli TV; Wagener MM; Singh N
    Transpl Immunol; 2010 Aug; 23(4):166-9. PubMed ID: 20609386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Cytomegalovirus Infection on Survival of Older Kidney Transplant Patients (D+/R+): Impact of Valganciclovir Prophylaxis Versus Preemptive Therapy.
    Luna E; Caravaca F; Ferreira F; Fernandez N; Martín P; Vargas ML; Saenz de Santamaría J; Garcia Pino G; Azevedo L; Muñoz Sanz A
    Transplant Proc; 2016 Nov; 48(9):2931-2937. PubMed ID: 27932110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
    Singh N; Wannstedt C; Keyes L; Gayowski T; Wagener MM; Cacciarelli TV
    Transplantation; 2005 Jan; 79(1):85-90. PubMed ID: 15714174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
    Strippoli GF; Hodson EM; Jones C; Craig JC
    Transplantation; 2006 Jan; 81(2):139-45. PubMed ID: 16436954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients.
    Liu AW; Jutivorakool K; Fisher CE; Rakita RM; Reyes JD; Bhattacharya RB; Jerome KR; Limaye AP
    Transplantation; 2018 Apr; 102(4):632-639. PubMed ID: 29215460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
    Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R
    Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.